Surgery Partners (NASDAQ:SGRY) Stock Rating Reaffirmed by Cantor Fitzgerald

Surgery Partners (NASDAQ:SGRY)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $43.00 price objective on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 82.20% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Benchmark reissued a “buy” rating and set a $50.00 target price on shares of Surgery Partners in a research note on Wednesday, May 1st. Barclays began coverage on Surgery Partners in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $35.00 price target on the stock. Macquarie began coverage on Surgery Partners in a research report on Friday, June 28th. They issued an “outperform” rating and a $31.00 price target on the stock. Citigroup reduced their price target on Surgery Partners from $42.00 to $38.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, StockNews.com raised Surgery Partners from a “sell” rating to a “hold” rating in a research report on Thursday, March 21st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.38.

Surgery Partners Price Performance

SGRY opened at $23.60 on Tuesday. The stock’s 50-day moving average price is $25.37 and its 200 day moving average price is $28.66. Surgery Partners has a 12-month low of $22.05 and a 12-month high of $44.88. The company has a current ratio of 1.71, a quick ratio of 1.56 and a debt-to-equity ratio of 0.92. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of 27.66, a PEG ratio of 1.80 and a beta of 2.78.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Surgery Partners had a return on equity of 3.65% and a net margin of 0.02%. The firm had revenue of $717.40 million for the quarter, compared to analyst estimates of $707.66 million. As a group, sell-side analysts expect that Surgery Partners will post 0.88 earnings per share for the current year.

Insider Transactions at Surgery Partners

In other news, insider Bradley R. Owens sold 6,000 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $27.65, for a total transaction of $165,900.00. Following the sale, the insider now owns 72,338 shares of the company’s stock, valued at approximately $2,000,145.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.30% of the company’s stock.

Institutional Investors Weigh In On Surgery Partners

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mesirow Institutional Investment Management Inc. raised its position in shares of Surgery Partners by 12.4% during the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 3,388 shares of the company’s stock worth $108,000 after acquiring an additional 373 shares in the last quarter. Natixis Advisors L.P. grew its stake in Surgery Partners by 8.6% during the 4th quarter. Natixis Advisors L.P. now owns 11,735 shares of the company’s stock worth $375,000 after buying an additional 934 shares during the last quarter. ProShare Advisors LLC grew its stake in Surgery Partners by 7.8% during the 1st quarter. ProShare Advisors LLC now owns 13,588 shares of the company’s stock worth $405,000 after buying an additional 986 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Surgery Partners by 102.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 2,723 shares of the company’s stock worth $80,000 after buying an additional 1,375 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in Surgery Partners by 16.3% during the 1st quarter. Principal Financial Group Inc. now owns 10,073 shares of the company’s stock worth $300,000 after buying an additional 1,409 shares during the last quarter.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.